Management and Outcomes of Major Bleeding during Treatment with Dabigatran or Warfarin
نویسندگان
چکیده
Coagulation Unit, Hematology Center, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden; Dept of Medicine, Soonchunhyang University Gumi’s Hospital, North Kyungsang Province, South Korea; McMaster University, Population Health Research Institute, Hamilton, ON, Canada; Lankenau Medical Center, Thomas Jefferson Medical College, Wynnewood, PA; Uppsala Clinical Research Center and Dept of Medical Sciences, Uppsala University, Uppsala, Sweden; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany; Dept of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
منابع مشابه
Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review
abstract:Acute Venous Thromboembolism (VTE) is a common disease associated with the significant morbidity and mortality. We reviewed clinical outcomes systematically with Dabigatran as a direct oral anticoagulants (DOAC) for treatment of acute VTE. We used Ovide, PubMed, Cochrane (CENTRAL), EMBASE, Scopus, Science Direct, LILAC(for article written not English) and also Iranian database; Magiran...
متن کاملComparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review
abstract:Acute Venous Thromboembolism (VTE) is a common disease associated with the significant morbidity and mortality. We reviewed clinical outcomes systematically with Dabigatran as a direct oral anticoagulants (DOAC) for treatment of acute VTE. We used Ovide, PubMed, Cochrane (CENTRAL), EMBASE, Scopus, Science Direct, LILAC(for article written not English) and also Iranian database; Magiran...
متن کاملConservative Management of Dabigatran Overdose: Case Report and Review of Literature
Background: Direct thrombin inhibitors and factor Xa inhibitors are gaining popularity as alternatives to warfarin for patients requiring anticoagulation. Toxicity due to these medications is difficult to manage because overdose experience is very limited and there is no clear guidance on when or whether to use antidote in this setting. Case Presentation: A 50-year-old man with normal renal fu...
متن کاملLetter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
BACKGROUND The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. METHODS AND RESULTS Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with maj...
متن کاملAnticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
BACKGROUND AND PURPOSE Little is known about the clinical outcomes associated with posthemorrhage anticoagulation resumption for atrial fibrillation. This study had 2 objectives: first, to evaluate anticoagulation use after a first major bleed on warfarin or dabigatran and, second, to compare effectiveness and safety outcomes between patients discontinuing anticoagulation after a major bleed an...
متن کاملPrediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study
OBJECTIVES To compare stratified event rates from randomized controlled trials with predicted event rates from models developed in observational data, and assess their ability to accurately capture observed rates of thromboembolism and major bleeding for patients treated with dabigatran or warfarin as part of routine care. DESIGN New initiator cohort study. SETTING Data from United Healt...
متن کامل